Myeloma Active Clinical Trials
Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.
Need More Information About a Particular Clinical Trial? Contact Us
To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.
Trials Currently Recruiting Participants - Myeloma Committee
STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN)ACCRUAL
GOALDATE
ACTIVATEDEDUCATIONAL MATERIALS
EAA172 A Phase I/II Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status
Note: Enrollment suspended. This trial will re-open as soon as a protocol amendment is completed.Michael A. Thompson, MD, PhD, Chair
Murali Janakirum, MD, Co-Chair
Sagar Lonial, MD, Co-Chair
(Susanna Jacobus, ScM)282 01/25/2019 EAA172 Resources
EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Natalie S. Callander, MD, Chair
Sagar Lonial, MD, Co-Chair
(Susanna Jacobus, ScM)288 04/30/2019 EAA173 Resources
Download
© 2019 ECOG-ACRIN Cancer Research Group. All rights reserved. | Disclaimer